-
Mashup Score: 3Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer - 4 day(s) ago
A novel urine biomarker test may help reduce the number of cystoscopies necessary in high-risk patients with bladder cancer, according to findings presented at the European Association of Urology Cong…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer - 5 day(s) ago
A novel urine biomarker test may help reduce the number of cystoscopies necessary in high-risk patients with bladder cancer, according to findings presented at the European Association of Urology Cong…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
“In the preclinical space, we continue to be interested in trying to understand the mechanistic underpinnings of these combination therapies,” says Kent W. Mouw, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0
Patients with muscle-invasive bladder cancer who remain molecular residual disease negative following cystectomy may be spared from adjuvant therapy.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4The Role of Circulating Tumor DNA in Bladder Cancer - 12 day(s) ago
Following a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
A comprehensive discussion on treatment-related adverse events seen in patients receiving enfortumab vedotin and pembrolizumab.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Neoadjuvant pembrolizumab appeared to offer more favorable results among both cisplatin-eligible and cisplatin-ineligible patients.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 5
The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In an interview with Targeted Oncology, Joseph M. Jacob, MD, discussed how bladder preservation is the top reason for refusal of radical cystectomy in the TAR-200 monotherapy cohort of the SunRISe-1 study.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Upfront Surgery May Be Avoidable in Very High-Risk NMIBC Responsive to BCG - Renal and Urology News - 16 day(s) ago
Within 5 years, 22% of patients with very high-risk NMIBC treated with adequate BCG had disease progression
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
RT @ASCOPost: Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer https://t.co/PcDwhZeIeF #blcsm…